Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity.
dell'Omo
Roberto
R
Kulkarni
Avinash
A
Franks
Wendy A
WA
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007231:Infant, Newborn; D007267:Injections; D007429:Intraocular Pressure; D007498:Iris / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D012163:Retinal Detachment / Q000209:etiology; D012178:Retinopathy of Prematurity / Q000150:complications*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab